Biotech companies at ACT 2026
Nov 15–18, 2026 San Antonio, TX ~1.4k attendees Website
22 biotech companies are at ACT 2026 — 28 presentations on the program. Most represented: Spyre Therapeutics (2 on the program), Enveda (1 on the program), Neurocrine Biosciences (1 on the program). 7 of them have their own page in this guide. As of Oct 8, 2026.
Topic
Top represented
Showing 1–17 of 22 organizations
| Organization | ACT 2026 Attendance |
|---|---|
Clinical-stage biotech developing half-life-extended antibodies and antibody combinations for inflammatory bowel disease and other immune-mediated diseases. | Poster Mon Nov 16 5:00pm–6:30pm |
Enveda Boulder, CO | |
Biotech discovering medicines from natural-product chemistry with AI; chairs a course on genetic toxicology in drug development. | Talk Sun Nov 15 1:00pm–1:30pm Session Sun Nov 15 1:00pm–4:30pm Navigating Genetic Toxicology through Drug Development: Interface of Practice, Strategy, and Regulatory Principles (CE7)
Talk Sun Nov 15 4:00pm–4:30pm |
Neurocrine Biosciences San Diego, CA | ◆Gold Supporter |
Biopharmaceutical company developing treatments for neurological, psychiatric, endocrine and immune disorders. | Session Tue Nov 17 2:00pm–5:00pm From Policy to Practice: Progress on the FDA’s 2025 Roadmap to Reduce Animal Use in Antibody Platform Development (S12)
Talk Tue Nov 17 2:00pm–2:05pm |
Biotech developing medicines for neurodegenerative diseases that are engineered to cross the blood–brain barrier. | Session Mon Nov 16 9:00am–12:00pm Beyond the Vessel Wall: Translational Insights into Vascular Inflammation (S03)
Talk Mon Nov 16 9:00am–9:15am |
QurAlis Cambridge, MA | |
Biotech developing precision medicines for ALS, frontotemporal dementia and other neurodegenerative diseases. | Talk Tue Nov 17 9:00am–9:05am Session Tue Nov 17 9:00am–12:00pm Overcoming the Blood-Brain Barrier and Translational Challenges in the Nonclinical Development of CNS Drugs (S08)
|
Regeneron Tarrytown, NY | |
Biotech company that discovers, develops and markets antibody medicines and is building gene therapies, including for genetic hearing loss. | Session Wed Nov 18 9:00am–12:00pm Do You Hear What I Hear? Evaluating Otic and Vestibular Toxicity in Clinical Development (S14)
Talk Wed Nov 18 9:50am–10:15am |
Agios Pharmaceuticals Cambridge, MA | |
Biotech company developing medicines for rare diseases, including inherited blood disorders such as pyruvate kinase deficiency and thalassemia. | Talk Tue Nov 17 2:50pm–3:15pm |
Aligos Therapeutics South San Francisco, CA | |
Biotech developing medicines for chronic hepatitis B and liver disease; presents preclinical data on an HBV antisense oligonucleotide. | |
BioMarin San Rafael, CA | |
Biotech company developing and marketing treatments for rare genetic diseases, including enzyme replacement therapies. | Session Wed Nov 18 2:00pm–3:15pm The Versatile Toxicologist: How to Leverage Expertise into Opportunity (S16)
|
Clinical-stage cell therapy developer owned by Bayer, building cell replacement treatments for neurological and eye diseases. | Talk Wed Nov 18 2:20pm–2:40pm |
Disc Medicine Watertown, MA | |
Biotech developing hematology medicines that act on hepcidin and iron; presents carcinogenicity risk assessments for two antibodies. | |
Dyne Therapeutics Waltham, MA | |
Biotech developing oligonucleotide medicines for neuromuscular diseases; presents data on delivering them to the central nervous system of monkeys. | |
Editas Medicine Cambridge, MA | |
Genome-editing company developing in vivo CRISPR-based gene therapies. | Talk Mon Nov 16 3:45pm–4:15pm |
EM EvoN Medics | |
Developer of products for neurological conditions; presents a rat study of a drug protecting against aluminum-induced neurotoxicity. | |
IDEAYA Biosciences South San Francisco, CA | |
Oncology biotech developing precision medicines, including synthetic-lethality drugs, for genetically defined cancers. | Session Mon Nov 16 9:00am–12:00pm From China to the World: De-risking Nonclinical Safety Packages to Ensure Regulatory Acceptance (S01)
|
Ignota Labs Cambridge, UK | |
AI-driven company that rescues shelved drug candidates, using a machine-learning safety platform to predict off-target toxicity mechanisms. | Talk Sun Nov 15 10:00am–10:30am |
Ionis Pharmaceuticals Carlsbad, CA | |
Develops RNA-targeted antisense oligonucleotide medicines, with marketed drugs for neurological and cardiometabolic diseases. |
Instantly find 20 buyers from biotech companies
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Browse ACT 2026 by
Organization type
Topic
- Nonclinical strategy and regulatory 58
- New approach methods 54
- Biologics and new modalities 43
- Chemical and environmental risk assessment 38
- Neurotoxicology 35
- Animal models and in vivo studies 35
- Bioanalysis, ADME and biomarkers 34
- In silico toxicology and AI 34
- Genetic toxicology and carcinogenicity 25
- Pathology 22
- Translational and clinical safety 22
- Safety pharmacology 21
- Immunotoxicology 21
- Developmental and reproductive toxicology 21
- Study data and software 12
- Inhalation toxicology 11
- Careers 5
Exhibit hall
Everyone
Not affiliated with or endorsed by the American College of Toxicology (ACT). Organization details are derived from ACT’s published program, exhibitor floor plan and supporter list, and each organization’s own website. Submit a correction